Neuromuscular Junction Diseases Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Neuromuscular Junction Diseases. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Neuromuscular Junction Diseases Indian Medical PG Question 1: The diagnosis of myasthenia gravis is made by a positive edrophonium test, repetitive nerve stimulation test of a weak muscle, and anti-acetylcholine receptor antibody assay. MRI of the mediastinum is now indicated to:
- A. Rule out thymoma (Correct Answer)
- B. Look for small cell carcinoma and Lambert-Eaton syndrome
- C. Rule out sarcoidosis
- D. Rule out tuberculosis before starting prednisone
Neuromuscular Junction Diseases Explanation: ***Rule out thymoma***
- Up to 15% of patients with **myasthenia gravis** also have a **thymoma**, a tumor of the thymus gland, which is visible on mediastinal imaging [1].
- Surgical removal of the thymoma can lead to improvement in myasthenic symptoms or even remission in some patients.
*Look for small cell carcinoma and Lambert-Eaton syndrome*
- While **small cell carcinoma** is associated with **Lambert-Eaton myasthenic syndrome (LEMS)**, myasthenia gravis is not typically linked to this specific cancer or paraneoplastic syndrome in the same way [2].
- LEMS is characterized by proximal muscle weakness that *improves* with repeated effort, and a different antibody profile (anti-voltage-gated calcium channels) than myasthenia gravis [2].
*Rule out sarcoidosis*
- **Sarcoidosis** is a granulomatous disease that can affect various organs, including the lungs and lymph nodes, but it is not directly associated with the pathophysiology of myasthenia gravis, nor is mediastinal MRI a primary diagnostic tool for sarcoidosis in the context of myasthenia diagnosis.
- The clinical presentation and diagnostic pathway for sarcoidosis differ significantly from those for myasthenia gravis.
*Rule out tuberculosis before starting prednisone*
- Ruling out **tuberculosis** is indeed important before initiating **prednisone** due to the immunosuppressive effects of corticosteroids.
- However, the primary indication for mediastinal MRI in a newly diagnosed myasthenia gravis patient is specifically to assess the thymus for **thymoma**, not to screen for tuberculosis [1].
Neuromuscular Junction Diseases Indian Medical PG Question 2: The mechanism of action of botulinum toxin primarily involves disruption of:
- A. Muscle transmission
- B. Non-neuromuscular transmission
- C. Neuromuscular transmission (Correct Answer)
- D. Neural transmission
Neuromuscular Junction Diseases Explanation: ***Neuromuscular transmission***
- **Botulinum toxin** acts at the **neuromuscular junction**, specifically targeting proteins involved in **neurotransmitter** (acetylcholine) release.
- It cleaves **SNARE proteins** (SNAP-25, synaptobrevin, syntaxin), thereby preventing the fusion of synaptic vesicles with the presynaptic membrane and the subsequent release of **acetylcholine**, leading to muscle paralysis.
- This is the primary and most specific mechanism of action of botulinum toxin produced by *Clostridium botulinum*.
*Muscle transmission*
- This option is too general; while muscle function is affected, the primary disruption is at the **junction between nerves and muscles**, not directly within the muscle fiber itself.
- The toxin's action is on the **presynaptic nerve terminal**, preventing the signal from reaching the muscle, rather than interfering with the muscle's internal contraction mechanism.
*Non-neuromuscular transmission*
- This is incorrect as **botulinum toxin** specifically targets and disrupts the process of **neuromuscular transmission**, not non-neuromuscular pathways.
- Its effects are localized to the **cholinergic nerve terminals**, which are abundant at neuromuscular junctions.
*Neural transmission*
- While it affects parts of the nervous system, stating "neural transmission" is too broad. The toxin is highly specific to the **peripheral cholinergic nerve terminals** at the neuromuscular junction, not general neural transmission throughout the central or peripheral nervous system.
- It does not disrupt the conduction of action potentials along the nerve axon but rather the **release of neurotransmitters** at the synapse.
Neuromuscular Junction Diseases Indian Medical PG Question 3: Sequence the events in neuromuscular action potential conduction:
1. Sodium channels open in the end plate
2. Calcium enters at the nerve terminal
3. Release of acetylcholine
- A. $1 \rightarrow 2 \rightarrow 3$
- B. $1 \rightarrow 3 \rightarrow 2$
- C. $3 \rightarrow 2 \rightarrow 1$
- D. $2 \rightarrow 3 \rightarrow 1$ (Correct Answer)
Neuromuscular Junction Diseases Explanation: ***Correct: $2 \rightarrow 3 \rightarrow 1$***
- **Calcium entry at the nerve terminal** is the initial trigger - when an action potential reaches the presynaptic nerve terminal, voltage-gated calcium channels open, allowing Ca²⁺ influx
- **Acetylcholine release** follows - the increased intracellular calcium causes synaptic vesicles containing acetylcholine to fuse with the presynaptic membrane and release the neurotransmitter into the synaptic cleft
- **Sodium channels open in the end plate** last - acetylcholine binds to nicotinic receptors on the motor end plate, opening ligand-gated sodium channels, which depolarizes the muscle membrane and triggers muscle contraction
*Incorrect: $1 \rightarrow 2 \rightarrow 3$*
- Places sodium channel opening first, which is physiologically impossible
- Sodium channels at the motor end plate only open in response to acetylcholine binding
- Cannot occur before acetylcholine is released from the nerve terminal
*Incorrect: $1 \rightarrow 3 \rightarrow 2$*
- Incorrectly sequences sodium channel opening before calcium entry
- Violates the fundamental principle that calcium influx is required for neurotransmitter release
- Acetylcholine cannot be released without prior calcium entry
*Incorrect: $3 \rightarrow 2 \rightarrow 1$*
- Places acetylcholine release before calcium entry, which is impossible
- Calcium-triggered exocytosis is an absolute requirement for neurotransmitter release
- Without calcium influx, vesicles cannot fuse with the presynaptic membrane
Neuromuscular Junction Diseases Indian Medical PG Question 4: Which of the following is true regarding weakness in myasthenia gravis?
- A. Deep tendon reflexes are lost
- B. Only skeletal muscles are involved (Correct Answer)
- C. Associated with sensory loss
- D. Associated with some degree of altered sensorium
Neuromuscular Junction Diseases Explanation: ***Only skeletal muscles are involved***
- Myasthenia gravis is an **autoimmune disease** that primarily affects the **neuromuscular junction** of **skeletal muscles** [1], [2].
- This leads to **muscle weakness** and fatigue, but does not typically involve smooth or cardiac muscle.
*Deep tendon reflexes are lost*
- **Deep tendon reflexes** are typically **preserved** in myasthenia gravis, even in the presence of severe muscle weakness [3].
- The disease affects the transmission of impulses at the motor end plate, not the reflex arc itself.
*Associated with sensory loss*
- Myasthenia gravis is a **purely motor disorder** and does **not involve sensory nerves**.
- Patients will experience muscle weakness but maintain normal sensation.
*Associated with some degree of altered sensorium*
- Myasthenia gravis does **not directly affect the central nervous system** or cause altered consciousness.
- Any altered sensorium would suggest a different or coexisting neurological condition.
Neuromuscular Junction Diseases Indian Medical PG Question 5: All the following statements are true about Lambert Eaton syndrome except:
- A. Associated with small cell lung cancer in about 50-60% of cases
- B. Caused by antibodies against acetylcholine receptors at the neuromuscular junction
- C. Characterized by proximal muscle weakness that typically improves with exercise (Correct Answer)
- D. Shows incremental response on repetitive nerve stimulation testing
Neuromuscular Junction Diseases Explanation: ***Caused by antibodies against acetylcholine receptors at the neuromuscular junction***
- This statement is incorrect because **Lambert-Eaton Myasthenic Syndrome (LEMS)** is caused by antibodies against **presynaptic voltage-gated calcium channels (VGCCs)**, which impairs acetylcholine release [1].
- Antibodies against **acetylcholine receptors at the neuromuscular junction** are characteristic of **Myasthenia Gravis**, not LEMS [2].
*Associated with small cell lung cancer in about 50-60% of cases*
- This statement is true; LEMS is a **paraneoplastic syndrome**, most commonly associated with **small cell lung cancer (SCLC)** due to shared antigenic expression [1], [3].
- The antibodies targeting VGCCs in LEMS often develop in response to the immune system attacking SCLC cells [1].
*Characterized by proximal muscle weakness that typically improves with exercise*
- This statement is true; patients with LEMS often experience **proximal muscle weakness**, particularly in the lower limbs.
- A characteristic feature is the **Lambert-Eaton phenomenon**, where initial weakness temporarily improves with repeated muscle contraction or exercise due to increased mobilization of acetylcholine.
*Shows incremental response on repetitive nerve stimulation testing*
- This statement is true; **repetitive nerve stimulation (RNS) testing** in LEMS typically shows a characteristic **incremental (facilitatory) response** at high stimulation frequencies.
- This increment reflects the enhanced release of acetylcholine from the presynaptic terminal after repeated depolarization, distinguishing it from the decremental response seen in Myasthenia Gravis.
Neuromuscular Junction Diseases Indian Medical PG Question 6: Myasthenia gravis is a disorder of:
- A. Spinal cord
- B. Motor neuron
- C. Neuromuscular junction (Correct Answer)
- D. Peripheral nerve
Neuromuscular Junction Diseases Explanation: Neuromuscular junction
- **Myasthenia gravis** is an **autoimmune disorder** where antibodies attack **acetylcholine receptors** at the **neuromuscular junction**, impairing nerve-to-muscle communication [1], [2].
- This leads to characteristic **muscle weakness** that worsens with activity and improves with rest [2].
*Spinal cord*
- Disorders of the **spinal cord** typically involve sensory, motor, and autonomic deficits below the level of the lesion, often characterized by **spasticity** and **hyperreflexia**.
- **Myasthenia gravis** does not directly affect the spinal cord, and its symptoms are distinct from spinal cord pathologies.
*Motor neuron*
- **Motor neuron diseases** (e.g., **ALS**) primarily affect the motor neurons in the brain and spinal cord, leading to progressive **muscle atrophy**, **fasciculations**, and **weakness** due to **denervation**.
- Myasthenia gravis does not involve motor neuron degeneration; the neurons themselves are healthy.
*Peripheral nerve*
- **Peripheral nerve disorders** (e.g., **Guillain-Barré syndrome**) involve damage to nerves outside the brain and spinal cord, causing sensory changes (numbness, tingling), muscle weakness, and often **diminished reflexes**.
- While myasthenia gravis causes weakness, it is due to a problem at the junction between the nerve and muscle, not within the nerve itself.
Neuromuscular Junction Diseases Indian Medical PG Question 7: Lambert-Eaton Myasthenic Syndrome is associated with?
- A. Vitiligo
- B. Hyperthyroidism
- C. Small cell lung carcinoma (Correct Answer)
- D. All of the options
Neuromuscular Junction Diseases Explanation: ***Small cell lung carcinoma***
- **Lambert-Eaton Myasthenic Syndrome (LEMS)** is a paraneoplastic syndrome, most commonly associated with **small cell lung carcinoma (SCLC)** [1], [2].
- SCLC cells express **voltage-gated calcium channels** that are targeted by autoantibodies in LEMS, leading to impaired acetylcholine release [1].
*Vitiligo*
- **Vitiligo** is an autoimmune skin condition causing depigmentation and is generally associated with other autoimmune diseases, not LEMS.
- While both LEMS and vitiligo can involve immune dysregulation, there is no direct and common association between the two.
*Hyperthyroidism*
- **Hyperthyroidism**, particularly due to Graves' disease, is an autoimmune condition primarily affecting the thyroid gland.
- It is not a known direct or common association with LEMS. Myasthenia gravis, however, can be associated with hyperthyroidism.
*All of the options*
- While LEMS is an autoimmune disorder, its primary and most significant association is with **small cell lung carcinoma** [1], [3].
- The other conditions listed (vitiligo, hyperthyroidism) are not directly or commonly linked to LEMS.
Neuromuscular Junction Diseases Indian Medical PG Question 8: Which of the following is the MOST characteristic feature of Eaton-Lambert syndrome?
- A. Repeated electrical stimulation enhances muscle power in it. (Correct Answer)
- B. Neostigmine is not effective for this syndrome.
- C. It is commonly associated with small cell lung cancer.
- D. It can affect the ocular muscles.
Neuromuscular Junction Diseases Explanation: ***Repeated electrical stimulation enhances muscle power in it.***
- A hallmark feature of **Lambert-Eaton Myasthenic Syndrome (LEMS)** is the **potentiation of muscle strength** with repeated or high-frequency nerve stimulation [2].
- This is due to the disease pathophysiology where repeated stimulation allows the accumulation of **intracellular calcium**, leading to increased acetylcholine release at the neuromuscular junction.
*Neostigmine is not effective for this syndrome.*
- While it's largely true that **acetylcholinesterase inhibitors** like neostigmine are less effective in LEMS compared to myasthenia gravis, they can still provide some minor symptomatic relief [1].
- Therefore, stating it's *not effective* might be an oversimplification, and it's not the *most characteristic* feature.
*It is commonly associated with small cell lung cancer.*
- Although LEMS is frequently a **paraneoplastic syndrome** linked to **small cell lung cancer (SCLC)**, this association is a cause/etiology, not a direct characteristic feature of the neuromuscular dysfunction itself [1], [2].
- Approximately 50-60% of LEMS cases are paraneoplastic, with SCLC being the most common underlying malignancy [2].
*It can affect the ocular muscles.*
- **Ocular muscle involvement** (e.g., ptosis, diplopia) is a prominent and often initial symptom in **myasthenia gravis** [2].
- In LEMS, ocular muscle weakness is **much less common** and typically mild, if present, distinguishing it from myasthenia gravis.
Neuromuscular Junction Diseases Indian Medical PG Question 9: The electromyogram (EMG) is least useful for the diagnosis of:
- A. Myasthenia gravis
- B. Charcot-Marie-Tooth disease
- C. Spinal muscular atrophy
- D. Cerebral palsy (Correct Answer)
Neuromuscular Junction Diseases Explanation: ***Cerebral palsy***
- Cerebral palsy is a **disorder of movement and posture** caused by non-progressive brain damage, primarily affecting the **upper motor neurons**.
- While EMG can assess muscle activity, its primary role is in evaluating **lower motor neuron diseases** and **neuromuscular junction disorders**, making it less directly useful for diagnosing a central nervous system disorder like cerebral palsy.
*Myasthenia gravis*
- EMG, particularly **repetitive nerve stimulation**, is highly useful for diagnosing myasthenia gravis by revealing a **decremental response** in the compound muscle action potential due to impaired neuromuscular transmission [1].
- It directly assesses the function of the **neuromuscular junction**, which is the site of pathology in myasthenia gravis [1].
*Charcot-Marie-Tooth disease*
- EMG and **nerve conduction studies (NCS)** are crucial for diagnosing Charcot-Marie-Tooth disease by demonstrating **abnormal nerve conduction velocities** (demyelinating forms) or **reduced amplitude** of compound muscle action potentials (axonal forms) which indicate peripheral nerve damage.
- The findings help characterize the type and severity of **peripheral neuropathy**, a hallmark of this condition.
*Spinal muscular atrophy*
- EMG is essential for diagnosing spinal muscular atrophy by showing **denervation and reinnervation changes** in muscles, such as **fibrillations**, **positive sharp waves**, and **large-amplitude, long-duration motor unit potentials** [1].
- These findings reflect the loss of **anterior horn cells** and subsequent attempts by surviving motor neurons to reinnervate muscle fibers.
Neuromuscular Junction Diseases Indian Medical PG Question 10: A person was given a muscle relaxant that competitively blocks nicotinic receptors. Which of the following drugs is used for reversal of muscle relaxation after surgery?
- A. Succinylcholine
- B. Physostigmine
- C. Carbachol
- D. Neostigmine (Correct Answer)
Neuromuscular Junction Diseases Explanation: ***Neostigmine***
- **Neostigmine** is an **acetylcholinesterase inhibitor** that increases the amount of **acetylcholine** at the neuromuscular junction, allowing it to compete more effectively with the muscle relaxant for **nicotinic receptors**.
- By increasing the concentration of endogenous acetylcholine, it can reverse the effects of **competitive neuromuscular blockers**.
*Succinylcholine*
- **Succinylcholine** is a **depolarizing neuromuscular blocker** that initially activates and then desensitizes nicotinic receptors, causing transient fasciculations followed by paralysis.
- It would worsen muscle relaxation rather than reversing it, as it acts as an **agonist at nicotinic receptors**.
*Physostigmine*
- **Physostigmine** is an **acetylcholinesterase inhibitor** that readily crosses the **blood-brain barrier** and is primarily used for its central nervous system effects, such as reversing anticholinergic toxicity.
- While it prolongs the action of acetylcholine, its primary site of action and clinical uses are different from reversing peripheral muscle relaxation.
*Carbachol*
- **Carbachol** is a **direct-acting cholinergic agonist** that stimulates both **muscarinic** and **nicotinic receptors**.
- While it acts on nicotinic receptors, it would not be a suitable choice for reversing a competitive neuromuscular block as it also has significant **muscarinic side effects** and its direct agonism would not effectively overcome the competitive block.
More Neuromuscular Junction Diseases Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
